Charlene Kwong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Charlene Kwong has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Allan J. W. Lui
Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
5 shared publications - Christopher Antonio Febres-Aldana
Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
5 shared publications - Elisa de Stanchina
Antitumor Assessment Core, Memorial Sloan Kettering Cancer Center, New York, NY, USA
5 shared publications - Igor Odintsov
Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
5 shared publications - Inna Khodos
Memorial Sloan Kettering Cancer Center 7 Anti-tumor Core Facility New York, New York
5 shared publications - Irina Linkov
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
5 shared publications
Latest Publications
- Open Access
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Data from HER2 Antibody–Drug Conjugates Are Active against Desmoplastic Small Round Cell Tumor
Purpose:Desmoplastic small round cell tumor (DSRCT) is a rare but highly aggressive soft tissue sarcoma that arises in the abdominopelvic cavity of young males. Since the discovery of EWSR1::WT1 fusion as the driver of DSRCT, no actionable genomic alterations have been identified, limiting disease management to a combination of surgery, chemotherapy, and radiation, with very poor outcomes. Herein, we evaluated ERBB2/HER2 expression in DSRCT as a therapeutic target.Experimental Design:ERBB2/HER2 expression was assessed in clinical samples and patient-derived xenografts (PDX) using RNA sequencing, RT-qPCR, and a newly developed HER2 IHC assay (clone 29D8). Responses to HER2 antibody–drug conjugates (ADC)—trastuzumab deruxtecan (T-DXd) and trastuzumab emtansine—were evaluated in DSRCT PDX, cell line, and organoid models. Drug internalization was demonstrated by live microscopy. Apoptosis was evaluated by Western blotting and caspase activity assays.Results:ERBB2/HER2 was detectable in DSRCT samples from patients and PDXs, with higher sensitivity RNA assays and improved IHC detectability using clone 29D8. Treatment of ERBB2/HER2-expressing DSRCT PDX, cell line, and organoid models with T-DXd or trastuzumab emtansine resulted in tumor regression. This therapeutic response was long-lasting in T-DXd–treated xenografts and was mediated by rapid HER2 ADC complex internalization and cytotoxicity, triggering p53-mediated apoptosis and growth arrest. Xenograft regression was associated with bystander payload effects triggering global tumor niche responses proportional to HER2 status.Conclusions:ERBB2/HER2 is a therapeutic target in DSRCT. HER2 ADCs may represent novel options for managing this exceptionally aggressive sarcoma, possibly fulfilling an urgent and historically unmet need for more effective clinical therapy.
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from HER2 Antibody–Drug Conjugates Are Active against Desmoplastic Small Round Cell Tumor
Purpose:Desmoplastic small round cell tumor (DSRCT) is a rare but highly aggressive soft tissue sarcoma that arises in the abdominopelvic cavity of young males. Since the discovery of EWSR1::WT1 fusion as the driver of DSRCT, no actionable genomic alterations have been identified, limiting disease management to a combination of surgery, chemotherapy, and radiation, with very poor outcomes. Herein, we evaluated ERBB2/HER2 expression in DSRCT as a therapeutic target.Experimental Design:ERBB2/HER2 expression was assessed in clinical samples and patient-derived xenografts (PDX) using RNA sequencing, RT-qPCR, and a newly developed HER2 IHC assay (clone 29D8). Responses to HER2 antibody–drug conjugates (ADC)—trastuzumab deruxtecan (T-DXd) and trastuzumab emtansine—were evaluated in DSRCT PDX, cell line, and organoid models. Drug internalization was demonstrated by live microscopy. Apoptosis was evaluated by Western blotting and caspase activity assays.Results:ERBB2/HER2 was detectable in DSRCT samples from patients and PDXs, with higher sensitivity RNA assays and improved IHC detectability using clone 29D8. Treatment of ERBB2/HER2-expressing DSRCT PDX, cell line, and organoid models with T-DXd or trastuzumab emtansine resulted in tumor regression. This therapeutic response was long-lasting in T-DXd–treated xenografts and was mediated by rapid HER2 ADC complex internalization and cytotoxicity, triggering p53-mediated apoptosis and growth arrest. Xenograft regression was associated with bystander payload effects triggering global tumor niche responses proportional to HER2 status.Conclusions:ERBB2/HER2 is a therapeutic target in DSRCT. HER2 ADCs may represent novel options for managing this exceptionally aggressive sarcoma, possibly fulfilling an urgent and historically unmet need for more effective clinical therapy.
- Open Access
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures 1 from HER2 Antibody–Drug Conjugates Are Active against Desmoplastic Small Round Cell Tumor
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures 1 from HER2 Antibody–Drug Conjugates Are Active against Desmoplastic Small Round Cell Tumor
- Open Access
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from HER2 Antibody–Drug Conjugates Are Active against Desmoplastic Small Round Cell Tumor
Supplementary Table S2 from HER2 Antibody–Drug Conjugates Are Active against Desmoplastic Small Round Cell Tumor
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from HER2 Antibody–Drug Conjugates Are Active against Desmoplastic Small Round Cell Tumor
Supplementary Table S2 from HER2 Antibody–Drug Conjugates Are Active against Desmoplastic Small Round Cell Tumor
- Open Access
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from HER2 Antibody–Drug Conjugates Are Active against Desmoplastic Small Round Cell Tumor
Supplementary Table S1 from HER2 Antibody–Drug Conjugates Are Active against Desmoplastic Small Round Cell Tumor
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from HER2 Antibody–Drug Conjugates Are Active against Desmoplastic Small Round Cell Tumor
Supplementary Table S1 from HER2 Antibody–Drug Conjugates Are Active against Desmoplastic Small Round Cell Tumor
- Top Cited Papers
- 9 August 2024
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 30 (20) , 4701-4713
HER2 Antibody–Drug Conjugates Are Active against Desmoplastic Small Round Cell Tumor
Purpose: Desmoplastic small round cell tumor (DSRCT) is a rare but highly aggressive soft tissue sarcoma that arises in the abdominopelvic cavity of young males. Since the discovery of EWSR1::WT1 fusion as the driver of DSRCT, no actionable genomic alterations have been identified, limiting disease management to a combination of surgery, chemotherapy, and radiation, with very poor outcomes. Herein, we evaluated ERBB2/HER2 expression in DSRCT as a therapeutic target. Experimental Design: ERBB2/HER2 expression was assessed in clinical samples and patient-derived xenografts (PDX) using RNA sequencing, RT-qPCR, and a newly developed HER2 IHC assay (clone 29D8). Responses to HER2 antibody–drug conjugates (ADC)—trastuzumab deruxtecan (T-DXd) and trastuzumab emtansine—were evaluated in DSRCT PDX, cell line, and organoid models. Drug internalization was demonstrated by live microscopy. Apoptosis was evaluated by Western blotting and caspase activity assays. Results: ERBB2/HER2 was detectable in DSRCT samples from patients and PDXs, with higher sensitivity RNA assays and improved IHC detectability using clone 29D8. Treatment of ERBB2/HER2-expressing DSRCT PDX, cell line, and organoid models with T-DXd or trastuzumab emtansine resulted in tumor regression. This therapeutic response was long-lasting in T-DXd–treated xenografts and was mediated by rapid HER2 ADC complex internalization and cytotoxicity, triggering p53-mediated apoptosis and growth arrest. Xenograft regression was associated with bystander payload effects triggering global tumor niche responses proportional to HER2 status. Conclusions: ERBB2/HER2 is a therapeutic target in DSRCT. HER2 ADCs may represent novel options for managing this exceptionally aggressive sarcoma, possibly fulfilling an urgent and historically unmet need for more effective clinical therapy.
- 9 August 2024
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 30 (20) , 4701-4713
Top Cited PapersHER2 Antibody–Drug Conjugates Are Active against Desmoplastic Small Round Cell Tumor
Purpose: Desmoplastic small round cell tumor (DSRCT) is a rare but highly aggressive soft tissue sarcoma that arises in the abdominopelvic cavity of young males. Since the discovery of EWSR1::WT1 fusion as the driver of DSRCT, no actionable genomic alterations have been identified, limiting disease management to a combination of surgery, chemotherapy, and radiation, with very poor outcomes. Herein, we evaluated ERBB2/HER2 expression in DSRCT as a therapeutic target. Experimental Design: ERBB2/HER2 expression was assessed in clinical samples and patient-derived xenografts (PDX) using RNA sequencing, RT-qPCR, and a newly developed HER2 IHC assay (clone 29D8). Responses to HER2 antibody–drug conjugates (ADC)—trastuzumab deruxtecan (T-DXd) and trastuzumab emtansine—were evaluated in DSRCT PDX, cell line, and organoid models. Drug internalization was demonstrated by live microscopy. Apoptosis was evaluated by Western blotting and caspase activity assays. Results: ERBB2/HER2 was detectable in DSRCT samples from patients and PDXs, with higher sensitivity RNA assays and improved IHC detectability using clone 29D8. Treatment of ERBB2/HER2-expressing DSRCT PDX, cell line, and organoid models with T-DXd or trastuzumab emtansine resulted in tumor regression. This therapeutic response was long-lasting in T-DXd–treated xenografts and was mediated by rapid HER2 ADC complex internalization and cytotoxicity, triggering p53-mediated apoptosis and growth arrest. Xenograft regression was associated with bystander payload effects triggering global tumor niche responses proportional to HER2 status. Conclusions: ERBB2/HER2 is a therapeutic target in DSRCT. HER2 ADCs may represent novel options for managing this exceptionally aggressive sarcoma, possibly fulfilling an urgent and historically unmet need for more effective clinical therapy.